Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1948 3
1954 2
1955 1
1957 3
1958 4
1959 3
1964 1
1967 1
1968 2
1969 1
1973 1
2008 1
2009 2
2010 1
2011 1
2012 2
2015 2
2016 4
2017 2
2019 3
2020 4
2021 5
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Results by year

Filters applied: . Clear all
Page 1
First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.
Maitland ML, Sachdev JC, Sharma MR, Moreno V, Boni V, Kummar S, Stringer-Reasor E, Lakhani N, Moreau AR, Xuan D, Li R, Powell EL, Jackson-Fisher A, Bowers M, Alekar S, Xin X, Tolcher AW, Calvo E. Maitland ML, et al. Among authors: sachdev jc. Clin Cancer Res. 2021 Aug 15;27(16):4511-4520. doi: 10.1158/1078-0432.CCR-20-3757. Epub 2021 Jun 3. Clin Cancer Res. 2021. PMID: 34083232 Free PMC article.
Update on Precision Medicine in Breast Cancer.
Sachdev JC, Sandoval AC, Jahanzeb M. Sachdev JC, et al. Cancer Treat Res. 2019;178:45-80. doi: 10.1007/978-3-030-16391-4_2. Cancer Treat Res. 2019. PMID: 31209841
Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors.
Munster PN, Greenstein AE, Fleming GF, Borazanci E, Sharma MR, Custodio JM, Tudor IC, Pashova HI, Shepherd SP, Grauer A, Sachdev JC. Munster PN, et al. Among authors: sachdev jc. Clin Cancer Res. 2022 Aug 2;28(15):3214-3224. doi: 10.1158/1078-0432.CCR-21-4363. Clin Cancer Res. 2022. PMID: 35583817 Free PMC article. Clinical Trial.
Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial.
Patnaik A, Weiss GJ, Rasco DW, Blaydorn L, Mirabella A, Beeram M, Guo W, Lu S, Danaee H, McEachern K, Im E, Sachdev JC. Patnaik A, et al. Among authors: sachdev jc. Cancer Chemother Pharmacol. 2022 Jan;89(1):93-103. doi: 10.1007/s00280-021-04358-3. Epub 2021 Nov 8. Cancer Chemother Pharmacol. 2022. PMID: 34750637 Free PMC article. Clinical Trial.
Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers.
Jhaveri K, Chang MT, Juric D, Saura C, Gambardella V, Melnyk A, Patel MR, Ribrag V, Ma CX, Aljumaily R, Bedard PL, Sachdev JC, Dunn L, Won H, Bond J, Jones S, Savage HM, Scaltriti M, Wilson TR, Wei MC, Hyman DM. Jhaveri K, et al. Among authors: sachdev jc. Clin Cancer Res. 2021 Jan 15;27(2):447-459. doi: 10.1158/1078-0432.CCR-20-2657. Epub 2020 Nov 4. Clin Cancer Res. 2021. PMID: 33148674 Clinical Trial.
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial.
Kalinsky K, Hong F, McCourt CK, Sachdev JC, Mitchell EP, Zwiebel JA, Doyle LA, McShane LM, Li S, Gray RJ, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, O'Dwyer PJ, Harris LN, Arteaga CL, Chen AP, Flaherty KT. Kalinsky K, et al. Among authors: sachdev jc. JAMA Oncol. 2021 Feb 1;7(2):271-278. doi: 10.1001/jamaoncol.2020.6741. JAMA Oncol. 2021. PMID: 33377972 Free PMC article. Clinical Trial.
47 results